- Bright Minds Biosciences (DRUG) appoints drug development executive Mark A. Smith, M.D., Ph.D., as Chief Medical Officer
- Dr. Revati Shreeniwas’ engagement with Bright Minds as Chief Medical Officer has been terminated
- Dr. Smith has served as the Clinical Lead for Neuropsychiatry at Teva Pharmaceuticals
- Today he holds a position on the National Institute of Mental Health Translational Neuropsychopharmacology Task Force
- Bright Minds holds serotonin agonists designed to target neurocircuit abnormalities responsible for difficult-to-treat disorders
- Bright Minds Biosciences (DRUG) is down 1.50 per cent, trading at C$1.31 at 10:32 am EST
Bright Minds Biosciences (DRUG) welcomes Mark A. Smith, M.D., Ph.D., who will join them as Chief Medical Officer.
In addition to this news, Dr. Revati Shreeniwas’ engagement with Bright Minds as Chief Medical Officer has been terminated.
“I’m thrilled to welcome Dr. Smith to the Bright Minds team. A seasoned executive in CNS drug development, Dr. Smith, has directed over 50 clinical trials across all stages of development,” said Ian McDonald, CEO and Co-founder of Bright Minds Biosciences.
“His depth and breadth of knowledge in neuropsychiatry, development, translational neuroscience, and clinical trial design will be a great asset as we continue to advance our pipeline of novel compounds through clinical trials,” said McDonald.
Prior to joining Bright Minds, Dr. Smith was Chief Medical Officer at VistaGen Therapeutics, where he led the clinical development of drug candidates in the areas of major depression, social anxiety disorder, and depression through all phases of development.
Dr. Smith has served as the Clinical Lead for Neuropsychiatry at Teva Pharmaceuticals, where he was accountable for the strategy and clinical development of neuropsychiatric drugs with a focus on schizophrenia, sleep disorders, and agitation.
Before joining the pharmaceutical industry, he served as a Senior Staff Scientist of the Biological Psychiatry Branch and Senior Staff Fellow of the Clinical Neuroendocrinology Branch at the U.S. National Institute of Mental Health (NIMH).
Dr. Smith received his Bachelor’s degree and Master of Science from Yale University, his Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California, San Diego, and completed his residency in the Department of Psychiatry at Duke University Medical Center.
Today he holds a position on the National Institute of Mental Health Translational Neuropsychopharmacology Task Force.
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
Bright Minds holds serotonin agonists designed to target neurocircuit abnormalities responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain.
Bright Minds Biosciences (DRUG) is down 1.50 per cent, trading at C$1.31 at 10:32 am EST.
